奥沙利铂联合卡培他滨或替吉奥对进展期胃癌的疗效

Comparison of Efficacy of Oxaliplatin Combined With Capecitabine and Oxaliplatin Combined With Tegafur in the Treatment of Advanced Gastric Cancer

目的探讨奥沙利铂联合卡培他滨与奥沙利铂联合替吉奥治疗进展期胃癌的疗效。方法将2012年2月—2018年2月作为本次研究时间段,在该时间段内总共选取36例患者作为本次研究案例。按照随机数字法将36例患者划分为实验组与对照组。实验组采取奥沙利铂联合卡培他滨进行治疗,对照组采取奥沙利铂联合替吉奥进行治疗。结果实验组患者显效6例,有效10例,无效2例,总有效率88.89%;对照组患者显效7例,有效9例,无效2例,总有效率88.89%(P> 0.05)。结论奥沙利铂联合卡培他滨与奥沙利铂联合替吉奥治疗进展期胃癌的疗效相当,均具备较高的临床干预价值。

Abstract]Objective To investigate the efficacy of oxaliplatin combined with capecitabine and oxaliplatin combined with tegafur in the treatment of advanced gastric cancer.Methods From February 2012 to February 2018 as the study period,a total of 36 patients were selected as the study case.According to the random number method,36 patients were divided into experimental group and study group.The experimental group was treated with oxaliplatin and capecitabine,and the study group was treated with oxaliplatin combined with tegafur.Results In the experimental group,6 cases were markedly effective,10 cases were effective,and 2 cases were ineffective.The total effective rate was 88.89%.In the study group,7 cases were markedly effective,9 cases were effective,and 2 cases were ineffective.The total effective rate was 88.89%(P>0.05).Conclusion Oxaliplatin combined with capecitabine and oxaliplatin combined with tegafur are effective in the treatment of advanced gastric cancer,and all have high clinical intervention value.